Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0043167 (
pertussis
)
19,595
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mice were orally vaccinated with liposomes coated with filamentous hemagglutinin (FHA) and detoxified
pertussis
toxin (PT) of Bordetella
pertussis
. FHA- and PT-specific immunoglobulin G (IgG) was detected in serum, and both IgG and
IgA
were detected in lung washes following the immunization. Antibody responses in mice immunized with liposomes coated with FHA and PT were significantly higher than those in mice immunized with free FHA and PT, which demonstrated the adjuvanticity of the liposome carrier. The results indicate the potential usefulness of this approach for eliciting immune responses against FHA and PT (and perhaps other
pertussis
antigens) in humans and its possible utility in large-scale vaccination to protect against both B.
pertussis
infection and disease.
...
PMID:Antibody responses in the serum and respiratory tract of mice following oral vaccination with liposomes coated with filamentous hemagglutinin and pertussis toxoid. 842 87
Systemic and mucosal B-cell-mediated immune responses to purified filamentous hemagglutinin (FHA) in mice were analyzed at different times following a single respiratory infection with Bordetella
pertussis
. Serum immunoglobulin G (IgG) anti-FHA and respiratory IgG and
IgA
anti-FHA antibodies were first detected at 3 weeks postinfection, reached high levels by 8 weeks postinfection, and remained at high levels 12 to 32 weeks postinfection. FHA-specific B lymphocytes isolated from the spleens or lungs of uninfected control mice or mice convalescing from B.
pertussis
respiratory infection were analyzed in limiting-dilution cultures. Analysis of culture supernatants for the production of antibodies to FHA revealed an increased frequency of FHA-specific B cells of both the IgG- and the
IgA
-secreting classes in the lungs and tracheas of aerosol-challenged mice; these levels remained high as late as 25 weeks postinfection, compared with those in uninfected controls. No corresponding increase in the frequency of FHA-specific B cells in the spleens of aerosol-infected mice was observed. This long-lasting response observed in cultured cells was radiation resistant, a result suggesting that this response was due to B cells already activated in vivo. Polymerase chain reaction analysis revealed low but detectable levels of B.
pertussis
chromosomal DNA in 75% of mice tested at 8 weeks postinfection and 37.5% of mice tested at 26 weeks postinfection, at which times high levels of anti-FHA antibody were detected. One explanation for these data may be that, in this animal model, a major adhesin of B.
pertussis
can persist and interact with components of the immune system to stimulate the production of specific antibody in the respiratory tract many weeks after a single B.
pertussis
infection.
...
PMID:Long-lived respiratory immune response to filamentous hemagglutinin following Bordetella pertussis infection. 845 49
Intra-nasal immunization of mice with purified Bordetella
pertussis
filamentous haemagglutinin (FHA) or a crude cell sonicate was shown to protect against subsequent B.
pertussis
aerosol challenge. Immunization with FHA was found to be the most effective and resulted in complete clearance of the bacterial infection from the lungs within 14 days. Serum IgG and lung
IgA
anti-FHA antibodies were detectable within 4 weeks of the first immunization and anamnestic responses were seen following secondary immunization and subsequent challenge with B.
pertussis
. Nasal administration of
pertussis
antigens is a route which induces good systemic serum, as well as local secretory, antibody responses.
...
PMID:Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin. 847 3
Lipopolysaccharide (LPS) and outer membrane protein (OMP) preparations of Bordetella
pertussis
were incorporated into multilamellar liposomes composed of soya bean-derived phospholipids which were then used for oral and intranasal immunization of mice. Specific antibody responses of animals immunized by either route were measured in lung washes. A specific
IgA
response to LPS was detected after immunization with the OMP-containing liposomes but not with the LPS-containing liposomes, indicating adjuvant activity of the proteins. The OMP-containing liposomes were significantly more effective in inducing immune responses than the OMP preparation alone. Responses were highest when mice were given a booster 30 days after primary immunization. Maximum responses occurred 20 days after the booster but specific antibody was still detected 75 days after the secondary immunization. These results suggest that this liposome antigen delivery system has potential in stimulating secretory antibody responses which may be helpful in protecting against infection from B.
pertussis
.
...
PMID:Stimulation of secretory antibodies against Bordetella pertussis antigens in the lungs of mice after oral or intranasal administration of liposome-incorporated cell-surface antigens. 850 63
The aim of the study was to observe the frequency of occurrence of mycoplasmal antibodies detected by the complement fixation test (CFT), immunoelectroprecipitation test (IEPT) and ELISA in selected groups of patients with respiratory tract infections and to determine the dependence of these antibodies on the age of patients and length of illness. 521 serum samples collected from 404 persons were examined; 378 samples were obtained from 276 patients with pneumonia and 143 from 128 patients with upper respiratory tract infections. Additionally, serum samples from 50 patients with B.
pertussis
were investigated in this section of the study as a control test to demonstrate the specificity of the tests. It was established that in patients with pneumonia mycoplasmal antibodies are, as a rule, detected in much higher titers than in patients with upper respiratory tract infections. On with age, the level of mycoplasmal antibodies detected in all the three tests rose in the examined patients. In the highest titers antibodies against M. pneumoniae were detected in adults within the age 21-50. As a rule mycoplasmal IgM antibodies reached a level 2-3 times higher than IgG antibodies. It was also shown that already during the first week of illness antibodies against M. pneumoniae determined by the CFT, IEPT and ELISA in the sera of the examined persons are higher than the level known to be diagnostically significant. During the second week of illness
IgA
and IgM antibodies have a particularly high titer while the growth of titer of IgG antibodies is relatively small. A very high level of IgM, along with progressive growth of IgG antibodies and the related gradual decrease of the index value IgM/IgG, was observed in the serum of patients up to the 4th week of illness. In some cases, in titer known to be diagnostically significant, this high level was present even many months after the appearance of disease symptoms. Antibodies against M. pneumoniae in class of immunoglobulin A disappeared the fastest. Thus it is believed that demonstrating their characteristics dynamics or detecting these antibodies in the patient's serum in the titer assumed to be diagnostically significant can indicate an acute stage of illness.
...
PMID:[Evaluation of conventional and new generation tests for testing the humeral response to Mycoplasma pneumoniae antigens in natural infections in humans. II. Occurrence and level of mycoplasma antibodies in patients with respiratory tract infections]. 852 71
To investigate the frequency of unrecognized Bordetella
pertussis
infections in adults, we performed
IgA
and IgG ELISA antibody studies with four B.
pertussis
antigens--i.e., lymphocytosis-promoting factor, filamentous hemagglutinin, pertactin, and fimbriae-2--in 51 health care workers from whom six consecutive yearly serum samples (from 1984 to 1989) were available. Overall, 90% of the subjects had a significant increase in antibody (
IgA
or IgG) to one or more antigens between 2 consecutive years during the 5-year study period; 55% of subjects had evidence of two infections, 17% had three infections, and 4% had four infections. Infections occurred in all study years, with the following rates: 1984-1985, 32%; 1985-1986, 24%; 1986-1987, 40%; 1987-1988, 29%; and 1988-1989, 43% (P = .12). Some antibody rises may have been due to responses to cross-reacting antigens (Bordetella parapertussis, nontypable Haemophilus influenzae), but overall these data suggest that B.
pertussis
infections in adults are common, endemic, and usually unrecognized.
...
PMID:Frequency of unrecognized Bordetella pertussis infections in adults. 852 57
Household contacts of primary
pertussis
cases were evaluated. Infection was determined by culture, direct fluorescent antibody assay, and serological criteria. Agglutinin titers and values of ELISA IgG and
IgA
antibodies to lymphocytosis-promoting factor, filamentous hemagglutinin, and pertactin were determined. In 39 households 255 subjects were exposed; 114 remained well (group 1), 53 had mild illness (group 2), and 88 had
pertussis
(group 3). The infection rates were 46% (group 1), 43% (group 2), and 80% (group 3). In a subgroup of subjects seen within 14-28 days of exposure, it was found that none with clinical
pertussis
had a value of IgG antibody to pertactin in acute-phase sera of > or = 50 ELISA units (EU) per mL or an agglutinin titer of > 256. Of the primary cases, 53% were > or = 13 years of age. These data point out the importance of Bordetella
pertussis
infections in adolescents and adults as a source of infection in young children. Our subgroup data suggest that high values of antibody to pertactin and high agglutinin titers may be predictive of protection against clinical
pertussis
.
...
PMID:Household contact study of Bordetella pertussis infections. 858 45
The aim of this study was to validate the performance of the polymerase chain reaction (PCR) assay for Bordetella
pertussis
and Bordetella parapertussis in comparison with both culture and serology. The number of samples positive in PCR was 2.4-fold higher than the number of samples positive in culture. In serologically confirmed cases, the sensitivity of PCR and culture depended on the duration of disease and the age of the patient, being less sensitive in older age and later in disease. The sensitivity of the PCR in patients with < 10 days of symptoms was 70%, 50%, and 10% in the age groups < 1 year, 1-4 years, and > or = 5 years, respectively. Evidence suggested that the effect of age on sensitivity may be due to differences in immune responses. The low
IgA
response in the < 1 year age group may be related to the high number of samples positive in PCR and culture, even late in disease.
...
PMID:A clinical validation of Bordetella pertussis and Bordetella parapertussis polymerase chain reaction: comparison with culture and serology using samples from patients with suspected whooping cough from a highly immunized population. 865 19
The effect of formaldehyde treatment on the mucosal and systemic immunogenicity of the genetically detoxified
pertussis
toxin (PT-9K/129G) was investigated. Groups of BALB/c were immunized intranasally (i.n.) or subcutaneously (s.c.) with untreated, lightly formaldehyde treated (LFT) or heavily formaldehyde treated (HFT) recombinant
pertussis
toxin (PT) mutant, PT-9K/129G. Intranasal immunization with native PT-9K/ 129G induced significant levels of anti-toxin antibodies in serum and
IgA
anti-toxin responses in nasal and lung lavages of these mice. Similar local and systemic responses were observed following intransal immunization with LFT toxin. However, i.n. immunization with HFT toxin failed to induce a local
IgA
response and elicited a much diminished anti-toxin response in the serum. In contrast, the total antibody response following s.c. immunization was not significantly affected. In addition, i.n. immunization with native PT-9K/129G induced low but detectable levels of toxin neutralizing antibodies in the serum. These results show that native PT-9K/129G protein acts as a mucosal immunogen in mice and that this activity is greatly diminished by HFT of the protein.
...
PMID:Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment. 871 14
Antibody-binding epitopes on the Fim2 and Fim3 proteins of Bordetella
pertussis
, which have been associated with the induction of protective antibody, were located using sera from 12 patients with whooping cough and 4 vaccinated children. Fifteen epitopes were identified on both Fim2 and Fim3. In each case 9 were recognised by serum antibody from 11 or more infected patients. Epitopes associated with the highest IgG activity were not the same as those associated with the highest
IgA
activity. None of the vaccinated patients had detectable
IgA
. Most epitopes showed little or no evidence of serotype-specific responses, suggesting this is largely directed towards conformational epitopes. The reactivity of all but two epitopes was confirmed in an ELISA with patients' sera in which epitopes were re-synthesised as free soluble peptides. The short linear epitopes described may therefore be useful in the development of serodiagnostic assays but are unlikely vaccine candidates.
...
PMID:Epitope mapping the Fim2 and Fim3 proteins of Bordetella pertussis with sera from patients infected with or vaccinated against whooping cough. 873 Oct 26
<< Previous
1
2
3
4
5
6
7
8
9
10